The biotech industry is home to many large and prominent corporations, but there are also smaller and lesser-known drugmakers that are worth investors' consideration. Take Axsome Therapeutics (NASDAQ: AXSM) and Exelixis (NASDAQ: EXEL), two mid-cap biotechs with plenty to look forward to ahead.

Axsome and Exelixis may not be household names -- not yet, anyway -- but there are excellent reasons to think both could deliver solid returns over the next decade. Let's dig into why both biotech companies are worth investing in today.

In August, Axsome Therapeutics earned approval from the U.S. Food and Drug Administration (FDA) for Auvelity, a medicine for depression. It was an important milestone for the company that came at an opportune time to provide a fast-acting option to the growing number of people who suffer from symptoms of depression, a number that soared during the pandemic.

Continue reading

Source Fool.com